金河生物科技股份有限公司 2025 年半年度报告全文 2025 年半年度报告 2025 年 7 月 1 金河生物科技股份有限公司 2025 年半年度报告全文 2025 年半年度报告 第一节 重要提示、目录和释义 公司董事会、监事会及董事、监事、高级管理人员保证半年度报告内容 的真实、准确、完整，不存在虚假记载、误导性陈述或者重大遗漏，并承担 个别和连带的法律责任。 公司负责人王东晓、主管会计工作负责人牛有山及会计机构负责人(会计 主管人员)周立航声明：保证本半年度报告中财务报告的真实、准确、完整。 所有董事均已出席了审议本次半年报的董事会会议。 本报告中涉及的经营计划及目标，属于规划性事项，不构成公司对投资 者的实质承诺。投资者应对此保持足够的风险意识，应理解经营计划与业绩 承诺之间的差异。敬请广大投资者关注，并注意投资风险。 公司在本报告第三节"管理层讨论与分析"中"十、公司面临的风险和 应对措施"部分，详细描述了公司经营中可能存在的风险，敬请投资者关注 相关内容。 公司计划不派发现金红利，不送红股，不以公积金转增股本。 2 | | | | 第一节 重要提示、目录和释义 2 | | --- | | 第二节 ...

[Key Financial Data and Indicators](index=1&type=section&id=I.%20Key%20Financial%20Data%20and%20Indicators%20for%20the%20First%20Half%20of%202025) The company reported **4.78 billion Yuan** in total operating revenue, a 9.29% increase, and **240.23 million Yuan** in net profit attributable to shareholders, up 14.64%, reflecting enhanced core business profitability and modest asset growth Key Financial Data and Indicators for the First Half of 2025 | Item | Current Period | Prior Period | Change (%) | | :--- | :--- | :--- | :--- | | **Total Operating Revenue (Yuan)** | 4,783,647,091.70 | 4,377,131,366.47 | 9.29% | | **Operating Profit (Yuan)** | 289,745,305.87 | 244,269,852.05 | 18.62% | | **Net Profit Attributable to Shareholders (Yuan)** | 240,233,525.49 | 209,563,522.56 | 14.64% | | **Net Profit Attributable to Shareholders Excluding Non-Recurring Items (Yuan)** | 232,334,810.49 | 176,709,879.89 | 31.48% | | **Basic Earnings Per Share (Yuan)** | 0.3395 | 0.2970 | 14.31% | | **Weighted Average Return on Equity (%)** | 5.37% | 5.09% | Increase of 0.28 percentage points | | **Total Assets (Yuan)** | 16,727,370,408.27 | 16,100,437,077.47 | 3.89% (vs. Beginning of Period) | | **Total Equity Attributable to Shareholders (Yuan)** | 4,492,951,554.58 | 4,352,726,799.70 | 3.22% (vs. Beginning of Period) | [Explanation of Operating Performance and Financial Position](index=2&type=section&id=II.%20Explanation%20of%20Operating%20Performance%20and%20Financial%20Position) The company's performance growth was primarily driven by increased revenue from the smooth progress of ongoing general contracting projects and improved gross margins through enhanced project fine management and cost control [Analysis of Operating Revenue Growth](index=2&type=section&id=I.%20Primary%20Reasons%20for%20Year-on-Year%20Growth%20in%20Operating%20Revenue) The 9.29% year-on-year increase in operating revenue is primarily due to the steady progress of production and operations, with revenue recognized in line with the performance progress of ongoing general contracting projects - During the reporting period, the smooth progress of the company's ongoing general contracting projects led to a year-on-year increase in revenue recognized according to contract performance, serving as the primary driver for revenue growth[6](index=6&type=chunk) [Analysis of Net Profit Growth](index=2&type=section&id=II.%20Primary%20Reasons%20for%20Year-on-Year%20Growth%20in%20Net%20Profit%20Attributable%20to%20Shareholders%20of%20the%20Listed%20Company) The 14.64% year-on-year increase in net profit attributable to shareholders is primarily due to both operating revenue growth and an improved overall project gross margin achieved through enhanced fine management and comprehensive cost control - Net profit growth benefited from the dual factors of revenue increase and improved project gross margin[6](index=6&type=chunk) - The company enhanced overall project gross margin by deepening fine management of engineering projects and comprehensively implementing project responsibility cost control[6](index=6&type=chunk) [Compliance Statement](index=2&type=section&id=III.%20Analysis%20of%20Performance%20Leakage%20Reasons%20and%20Stock%20Price%20Fluctuations) The company confirms no performance leakage or abnormal stock price fluctuations occurred during the reporting period - The company confirmed no performance leakage or abnormal stock price fluctuations[7](index=7&type=chunk) [Documents for Reference](index=2&type=section&id=V.%20Documents%20for%20Reference) The report lists relevant documents for reference, including financial statements signed and sealed by management, board explanations, and internal audit reports - Documents for reference include comparative balance sheets and income statements signed and sealed by the company's legal representative, chief accountant, and head of accounting; the board of directors' explanation regarding the performance express report; and the internal audit report signed by the head of the internal audit department[9](index=9&type=chunk)

广州维力医疗器械股份有限公司2025 年半年度报告 公司代码：603309 公司简称：维力医疗 广州维力医疗器械股份有限公司 2025 年半年度报告 1 / 152 广州维力医疗器械股份有限公司2025 年半年度报告 重要提示 一、 本公司董事会、监事会及董事、监事、高级管理人员保证半年度报告内容的真实性、准确 性、完整性，不存在虚假记载、误导性陈述或重大遗漏，并承担个别和连带的法律责任。 二、 公司全体董事出席董事会会议。 三、 本半年度报告未经审计。 四、 公司负责人韩广源、主管会计工作负责人祝一敏及会计机构负责人（会计主管人员）祝一 敏声明：保证半年度报告中财务报告的真实、准确、完整。 五、 董事会决议通过的本报告期利润分配预案或公积金转增股本预案 无 六、 前瞻性陈述的风险声明 √适用 □不适用 本报告所涉及的公司未来计划、发展战略等前瞻性陈述，不构成公司对投资者的实质性承诺，请 投资者注意投资风险。 七、 是否存在被控股股东及其他关联方非经营性占用资金情况 否 八、 是否存在违反规定决策程序对外提供担保的情况 否 九、 是否存在半数以上董事无法保证公司所披露半年度报告的真实性、准确性和完整性 否 十 ...

上海沿浦精工科技（集团）股份有限公司2025 年半年度报告 公司代码：605128 公司简称：上海沿浦 上海沿浦精工科技（集团）股份有限公司 2025 年半年度报告 1 / 237 上海沿浦精工科技（集团）股份有限公司2025 年半年度报告 重要提示 一、 本公司董事会及董事、高级管理人员保证半年度报告内容的真实性、准确性、完整性，不 存在虚假记载、误导性陈述或重大遗漏，并承担个别和连带的法律责任。 二、 公司全体董事出席董事会会议。 三、 本半年度报告未经审计。 四、 公司负责人周建清、主管会计工作负责人秦艳芳及会计机构负责人（会计主管人员）周建 明声明：保证半年度报告中财务报告的真实、准确、完整。 五、 董事会决议通过的本报告期利润分配预案或公积金转增股本预案 无 √适用 □不适用 本报告中所涉及的未来计划、发展战略等前瞻性描述不构成公司对投资者的实质承诺，敬请 投资者注意投资风险。 七、 是否存在被控股股东及其他关联方非经营性占用资金情况 否 八、 是否存在违反规定决策程序对外提供担保的情况 否 九、 是否存在半数以上董事无法保证公司所披露半年度报告的真实性、准确性和完整性 否 十、 重大风险提示 公司 ...

哈尔滨东安汽车动力股份有限公司2025 年半年度报告 公司代码：600178 公司简称：东安动力 哈尔滨东安汽车动力股份有限公司 2025 年半年度报告 1 / 138 哈尔滨东安汽车动力股份有限公司2025 年半年度报告 重要提示 一、 本公司董事会、监事会及董事、监事、高级管理人员保证半年度报告内容的真实性、准确 性、完整性，不存在虚假记载、误导性陈述或重大遗漏，并承担个别和连带的法律责任。 二、 公司全体董事出席董事会会议。 三、 本半年度报告未经审计。 四、 公司负责人陈笠宝、主管会计工作负责人王向坤及会计机构负责人（会计主管人员）管乐 声明：保证半年度报告中财务报告的真实、准确、完整。 五、 董事会决议通过的本报告期利润分配预案或公积金转增股本预案 无 六、 前瞻性陈述的风险声明 √适用 □不适用 本半年度报告中所涉及的未来计划、发展战略等前瞻性陈述不构成公司对投资者的实质承诺 ，请投资者注意投资风险。 七、 是否存在被控股股东及其他关联方非经营性占用资金情况 否 八、 是否存在违反规定决策程序对外提供担保的情况 否 九、 是否存在半数以上董事无法保证公司所披露半年度报告的真实性、准确性和完整性 否 ...

中兰环保科技股份有限公司 2025 年半年度报告全文 中兰环保科技股份有限公司 2025 年半年度报告 2025-052 2025 年 7 月 公司计划不派发现金红利，不送红股，不以公积金转增股本。 2 | 目录 | | --- | 1 中兰环保科技股份有限公司 2025 年半年度报告全文 第一节 重要提示、目录和释义 公司董事会及董事、高级管理人员保证半年度报告内容的真实、准确、 完整，不存在虚假记载、误导性陈述或者重大遗漏，并承担个别和连带的法 律责任。 公司负责人葛芳、主管会计工作负责人毛庆艳及会计机构负责人(会计主 管人员)毛庆艳声明：保证本半年度报告中财务报告的真实、准确、完整。 所有董事均已出席了审议本次半年报的董事会会议。 公司在本报告第三节"管理层讨论与分析"之"十 公司面临的风险和应 对措施"部分，详细描述了公司经营中可能存在的风险及应对措施，敬请投 资者关注相关内容。 | 第一节 重要提示、目录和释义 | | 2 | | --- | --- | --- | | 第二节 公司简介和主要财务指标 | | 6 | | 第三节 管理层讨论与分析 | | 9 | | 第四节 公司治理、环境和社会 | ...

[Important Notice, Table of Contents, and Definitions](index=2&type=section&id=Item%201.%20Important%20Notice%2C%20Table%20of%20Contents%2C%20and%20Definitions) This section provides essential disclaimers, defines key terms, and outlines the report's structure [Important Notice](index=2&type=section&id=Important%20Notice) The company's management guarantees the report's accuracy, while forward-looking statements are not commitments, and no profit distribution is planned for the period - Company management guarantees the truthfulness, accuracy, and completeness of the report[3](index=3&type=chunk) - The company highlighted multiple risks including market competition, rising labor costs, declining gross profit margins, new product R&D, goodwill impairment, and loss of core technical personnel[3](index=3&type=chunk) - The company plans no cash dividends, bonus shares, or capital reserve conversions for this semi-annual period[4](index=4&type=chunk) [Definitions](index=5&type=section&id=Definitions) This section defines key terms, including company entities, reporting period, industry-specific, financial, and legal terminology, essential for understanding the report - The reporting period is defined as January 1, 2025, to June 30, 2025[9](index=9&type=chunk) - Core technologies and products such as motion control systems, CNC machine tools, engraving machines, and laser cutting are defined[9](index=9&type=chunk)[10](index=10&type=chunk) [Company Profile and Key Financial Indicators](index=7&type=section&id=Item%202.%20Company%20Profile%20and%20Key%20Financial%20Indicators) This section introduces the company's background and presents its key financial performance metrics for the reporting period [Company Profile](index=7&type=section&id=Company%20Profile) Shanghai Weihong Electronic Technology Co., Ltd., listed on the Shenzhen Stock Exchange, specializes in R&D, production, and sales of industrial motion control systems Company Information | Item | Content | | :--- | :--- | | **Stock Abbreviation** | Weihong Shares | | **Stock Code** | 300508 | | **Listing Exchange** | Shenzhen Stock Exchange | | **Legal Representative** | Tang Tongkui | [Key Accounting Data and Financial Indicators](index=8&type=section&id=Key%20Accounting%20Data%20and%20Financial%20Indicators) Operating revenue grew by 9.51% to **RMB 260 million**, while net profit attributable to shareholders decreased by 28.86% to **RMB 29.248 million**, despite a 257.05% increase in operating cash flow Key Financial Indicators for H1 2025 | Indicator | Current Period | Prior Period | YoY Change | | :--- | :--- | :--- | :--- | | **Operating Revenue (RMB)** | 260,197,176.18 | 237,610,268.38 | 9.51% | | **Net Profit Attributable to Shareholders (RMB)** | 29,247,939.69 | 41,110,699.04 | -28.86% | | **Net Profit Attributable to Shareholders After Non-recurring Items (RMB)** | 29,023,839.35 | 32,362,776.70 | -10.32% | | **Net Cash Flow from Operating Activities (RMB)** | 47,645,748.08 | 13,344,461.55 | 257.05% | | **Basic Earnings Per Share (RMB/share)** | 0.2663 | 0.3768 | -29.33% | | **Weighted Average Return on Net Assets** | 3.72% | 5.65% | -1.93% | Non-recurring Gains and Losses | Item | Amount (RMB) | Explanation | | :--- | :--- | :--- | | **Gains/Losses from Disposal of Non-current Assets** | 6,516,251.81 | Disposal of investment properties | | **Government Grants** | 3,667,910.97 | - | | **Fair Value Change Gains/Losses on Financial Assets** | -9,239,925.74 | Fluctuations in securities investment market value | | **Total** | **224,100.34** | - | [Management Discussion and Analysis](index=10&type=section&id=Item%203.%20Management%20Discussion%20and%20Analysis) This section provides a comprehensive review of the company's operations, financial performance, and strategic outlook for the reporting period [Principal Business](index=10&type=section&id=I.%20Principal%20Business%20Activities%20During%20the%20Reporting%20Period) The company specializes in R&D, production, and sales of industrial motion control systems for CNC machine tools, utilizing a direct sales model and holding a leading position in niche markets - The company's principal business involves the R&D, production, and sales of industrial motion control systems, servo drive systems, and industrial IoT, primarily applied in CNC machine tools[27](index=27&type=chunk) - The company's main products are categorized into motion controllers (motion control cards and integrated motion controllers) and servo drives[28](index=28&type=chunk) - The company employs a direct sales model, with a production approach combining "in-house production + outsourced processing"[34](index=34&type=chunk)[37](index=37&type=chunk) - The company has achieved a leading competitive advantage in niche markets such as engraving, waterjet cutting, and laser cutting[39](index=39&type=chunk) [Analysis of Core Competencies](index=12&type=section&id=II.%20Analysis%20of%20Core%20Competencies) The company's core competencies include proprietary high-precision motion control technology, strong brand presence, networked direct sales, rapid customized service, and a stable professional team - The company possesses high-speed, high-precision motion control technology for complex curved surfaces, being one of the few domestic enterprises to fully master this core technology[41](index=41&type=chunk)[42](index=42&type=chunk)[43](index=43&type=chunk) - As of the end of the reporting period, the company and its subsidiaries cumulatively held **227 valid patents** (including **111 invention patents**) and **86 computer software copyrights**[44](index=44&type=chunk) - The company adopts a networked direct sales model, enabling direct customer engagement, ensuring pricing power, and providing fast, high-quality after-sales service[46](index=46&type=chunk) - The company possesses the ability to quickly meet personalized customer demands, establishing stable cooperative relationships through customized services[47](index=47&type=chunk)[48](index=48&type=chunk) [Analysis of Principal Business](index=14&type=section&id=III.%20Analysis%20of%20Principal%20Business) H1 2025 operating revenue grew **9.51%** to **RMB 260 million**, but net profit attributable to shareholders declined **28.86%** due to non-recurring items, despite growth across all business segments H1 2025 Performance Overview | Indicator | Amount (RMB) | YoY Growth | | :--- | :--- | :--- | | **Operating Revenue** | 260,197,176.18 | 9.51% | | **Net Profit Attributable to Shareholders** | 29,247,939.69 | -28.86% | | **Net Profit Attributable to Shareholders After Non-recurring Items** | 29,023,839.35 | -10.32% | - Revenue in all sub-segments achieved year-on-year growth: metal cutting market grew by **19%**, laser processing market by approximately **7%**, furniture decoration market by **6%**, and servo drive market by **15%**[53](index=53&type=chunk)[55](index=55&type=chunk)[57](index=57&type=chunk)[59](index=59&type=chunk) Operating Revenue by Product | Product | Operating Revenue (RMB) | Revenue YoY Growth | Gross Profit Margin | Gross Profit Margin YoY Change | | :--- | :--- | :--- | :--- | :--- | | **Control Card** | 70,050,809.74 | 2.33% | 80.17% | -5.84% | | **Integrated Machine** | 146,651,030.28 | 17.24% | 47.78% | -3.74% | | **Driver** | 29,448,897.00 | -3.87% | 34.48% | 5.21% | - Financial expenses increased by **544.58%** year-on-year, primarily due to increased financing interest; fair value change gains decreased by **253.91%** year-on-year due to securities investment market value fluctuations; asset disposal gains significantly increased year-on-year due to the disposal of investment properties[61](index=61&type=chunk) [Analysis of Non-Principal Business](index=17&type=section&id=IV.%20Analysis%20of%20Non-Principal%20Business) Non-principal businesses significantly impacted profit, with **RMB -14.29 million** in fair value change losses from securities investments being the primary driver of profit decline, partially offset by asset disposal gains and government grants Key Non-Principal Business Profit and Loss Items | Item | Amount (RMB) | % of Total Profit | Reason for Formation | | :--- | :--- | :--- | :--- | | **Investment Income** | 5,050,077.85 | 17.08% | Primarily bank wealth management and securities investment income | | **Fair Value Change Gains/Losses** | -14,290,003.59 | -48.34% | Primarily securities investment market value fluctuations | | **Asset Disposal Gains** | 6,516,251.81 | 22.04% | Primarily disposal of investment properties | | **Other Income** | 7,525,811.48 | 25.46% | Primarily government grants | [Analysis of Assets and Liabilities](index=18&type=section&id=V.%20Analysis%20of%20Assets%20and%20Liabilities) Total assets reached **RMB 976 million**, growing **3.35%** from year-end, with increased proportions of accounts receivable and inventory, and decreased proportions of accounts receivable financing and investment properties - Total assets at period-end were **RMB 976 million**, an increase of **3.35%** from the end of the previous year; net assets attributable to shareholders were **RMB 790 million**, an increase of **2.15%**[18](index=18&type=chunk) - Accounts receivable as a percentage of total assets increased from **5.37%** to **8.82%**, and inventory proportion increased from **4.10%** to **6.75%**[70](index=70&type=chunk) - Accounts receivable financing proportion decreased from **5.78%** to **1.52%**, primarily due to net changes in notes receivable; investment properties were cleared due to disposal[70](index=70&type=chunk)[73](index=73&type=chunk) [Analysis of Investment Status](index=19&type=section&id=VI.%20Analysis%20of%20Investment%20Status) The company actively invested in financial assets and entrusted wealth management, with fair value financial assets totaling **RMB 246 million** and an outstanding entrusted wealth management balance of **RMB 70.9449 million** Financial Assets Measured at Fair Value | Asset Category | Initial Investment Cost (RMB) | Fair Value Change Gains/Losses for the Period (RMB) | Period-end Amount (RMB) | | :--- | :--- | :--- | :--- | | **Stocks** | 106,815,521.19 | -13,883,932.20 | 176,227,783.60 | | **Others (Wealth Management)** | 105,379,115.64 | -406,071.39 | 69,799,297.99 | | **Total** | **212,194,636.83** | **-14,290,003.59** | **246,027,081.59** | Overview of Entrusted Wealth Management (Unit: RMB 10,000) | Specific Type | Entrusted Wealth Management Amount Incurred | Outstanding Balance | | :--- | :--- | :--- | | **Bank Wealth Management Products** | 6,134.82 | 5,294.49 | | **Brokerage Wealth Management Products** | 1,300 | 1,300 | | **Other Categories** | 500 | 500 | | **Total** | **7,934.82** | **7,094.49** | [Analysis of Major Holding and Participating Companies](index=21&type=section&id=VIII.%20Analysis%20of%20Major%20Holding%20and%20Participating%20Companies) Major subsidiaries Nanjing Kaitong and Shanghai Weihong Intelligent reported net profits of **RMB 5.629 million** and **RMB 7.769 million** respectively, while Jiangsu Feima incurred a **RMB 11.034 million** loss due to securities investment volatility Performance of Major Subsidiaries (Unit: RMB) | Company Name | Net Profit | | :--- | :--- | | **Shanghai Weihong Intelligent Technology Co., Ltd.** | 7,769,416.84 | | **Nanjing Kaitong Automation Technology Co., Ltd.** | 5,628,773.46 | | **Jiangsu Feima Investment Management Co., Ltd.** | -11,033,864.84 | - During the reporting period, Shanghai Hengzhida Laser Technology Co., Ltd. (51% stake) was added as a new controlled subsidiary, contributing **RMB 15,878.29** to the company's net profit[84](index=84&type=chunk) - Weihong Intelligent's performance declined due to decreased revenue; Jiangsu Feima's performance declined due to fluctuations in securities investment market value[85](index=85&type=chunk) [Risks and Countermeasures](index=22&type=section&id=X.%20Risks%20Faced%20by%20the%20Company%20and%20Countermeasures) The company faces risks including intensified market competition, rising costs, potential gross margin decline, R&D shortfalls, goodwill impairment, and talent loss, addressed by increased R&D, market expansion, and improved internal controls - Intensified market competition: The company will strengthen its industry position by increasing R&D investment and expanding its customer base[86](index=86&type=chunk) - Risk of declining gross profit margin: Servo drive products have lower gross profit margins, and their sales growth may reduce the overall gross profit margin[88](index=88&type=chunk) - Goodwill impairment risk: If subsidiary Nanjing Kaitong's future performance weakens, there remains a possibility of goodwill impairment[90](index=90&type=chunk) [Corporate Governance, Environment, and Society](index=25&type=section&id=Item%204.%20Corporate%20Governance%2C%20Environment%2C%20and%20Society) This section details the company's governance structure, environmental initiatives, and social responsibility efforts [Corporate Governance](index=25&type=section&id=Corporate%20Governance) The company elected a new independent director, plans no semi-annual profit distribution, and continues to implement restricted stock incentive plans for core employees - Independent Director Xu Liyun resigned, and Fan Liuqun was elected as the new independent director[96](index=96&type=chunk) - The company is implementing two phases of restricted stock incentive plans for 2023 and 2024 to retain core talent[98](index=98&type=chunk)[101](index=101&type=chunk) [Social Responsibility](index=28&type=section&id=Social%20Responsibility) The company actively fulfills social responsibilities by protecting stakeholders' rights and making donations to Qinghai earthquake relief and Sichuan Yibin education - The company strictly adheres to laws and regulations, ensuring truthful, accurate, and complete information disclosure, and communicates with investors through various channels[107](index=107&type=chunk) - In January 2025, the company donated **RMB 20,000** to the Minhang Representative Office of Shanghai Charity Foundation for Qinghai earthquake relief and **RMB 50,000** to the Yibin Education Foundation in Sichuan Province to support youth education[108](index=108&type=chunk) [Significant Matters](index=29&type=section&id=Item%205.%20Significant%20Matters) This section outlines key events and developments that occurred during the reporting period, impacting the company's operations and financial position [Explanation of Significant Matters](index=29&type=section&id=Explanation%20of%20Significant%20Matters) The company sold idle properties, cancelled **1,911,100** repurchased shares, and its subsidiary Nanjing Kaitong was re-certified as a high-tech enterprise, with no illegal guarantees or related-party issues - The company sold its self-owned office building located in Minhang, Shanghai, and completed the transfer procedures[133](index=133&type=chunk) - The company cancelled **1,911,100** repurchased shares, reducing total share capital from **109,836,120** shares to **107,925,020** shares[134](index=134&type=chunk) - Wholly-owned subsidiary Nanjing Kaitong Automation Technology Co., Ltd. was re-certified as a high-tech enterprise, valid for three years[133](index=133&type=chunk) - The company has no instances of controlling shareholder fund occupation, illegal external guarantees, or significant related-party transactions[111](index=111&type=chunk)[112](index=112&type=chunk)[117](index=117&type=chunk) [Share Changes and Shareholder Information](index=33&type=section&id=Item%206.%20Share%20Changes%20and%20Shareholder%20Information) This section details changes in the company's share capital and provides an overview of its shareholder structure [Share Change Status](index=33&type=section&id=Share%20Change%20Status) Total share capital decreased from **109,836,120** to **107,925,020** shares due to the cancellation of **1,911,100** repurchased shares, affecting only unrestricted shares Share Change Status | Share Category | Quantity Before Change | Quantity After Change | Change in Quantity | | :--- | :--- | :--- | :--- | | **Restricted Shares** | 26,852,872 | 26,852,872 | 0 | | **Unrestricted Shares** | 82,983,248 | 81,072,148 | -1,911,100 | | **Total Share Capital** | **109,836,120** | **107,925,020** | **-1,911,100** | - The share change was due to the company changing the purpose of **1,911,100** shares in its special repurchase securities account to cancellation, which was completed on June 20, 2025[139](index=139&type=chunk)[140](index=140&type=chunk) [Shareholder Information](index=35&type=section&id=Shareholder%20Information) As of period-end, the company had **14,886** common shareholders, with actual controllers Tang Tongkui and Zheng Zhikai holding over **50%** as parties acting in concert - The total number of common shareholders at the end of the reporting period was **14,886**[143](index=143&type=chunk) Shareholding of Top Two Shareholders | Shareholder Name | Shareholding Percentage | Number of Shares Held | | :--- | :--- | :--- | | **Tang Tongkui** | 32.25% | 34,805,069 | | **Zheng Zhikai** | 22.66% | 24,458,080 | - Actual controllers Mr. Tang Tongkui and Mr. Zheng Zhikai constitute parties acting in concert[144](index=144&type=chunk) [Bond-Related Information](index=38&type=section&id=Item%207.%20Bond-Related%20Information) This section provides details on any bond-related activities or outstanding bonds of the company during the reporting period [Bond Information](index=38&type=section&id=Bond%20Information) The company had no bond-related matters during the reporting period - The company had no bond-related matters during this reporting period[149](index=149&type=chunk) [Financial Report](index=39&type=section&id=Item%208.%20Financial%20Report) This section presents the company's complete financial statements, including the balance sheet, income statement, cash flow statement, and notes to the financial statements [Audit Report](index=39&type=section&id=Audit%20Report) The company's 2025 semi-annual financial report is unaudited - This semi-annual financial report is unaudited[151](index=151&type=chunk) [Financial Statements](index=39&type=section&id=Financial%20Statements) This section presents the consolidated and parent company balance sheets, income statements, cash flow statements, and statements of changes in owners' equity for H1 2025 - Includes consolidated and parent company balance sheets, income statements, cash flow statements, and statements of changes in owners' equity[152](index=152&type=chunk) [Significant Accounting Policies and Estimates](index=59&type=section&id=Significant%20Accounting%20Policies%20and%20Estimates) This section details the company's accounting policies and estimates for financial statement preparation, including revenue recognition, financial instruments, and reclassification of warranty expenses to cost of sales - Financial statements are prepared on a going concern basis, in accordance with enterprise accounting standards[198](index=198&type=chunk)[199](index=199&type=chunk) - Revenue recognition: The company recognizes revenue when the customer obtains control of the related goods, typically at the time of customer signing the delivery note or express receipt[288](index=288&type=chunk)[291](index=291&type=chunk) - Impairment of financial instruments: For financial assets measured at amortized cost, loss provisions are recognized based on expected credit losses[233](index=233&type=chunk) - Change in accounting policy: In accordance with new regulations, warranty-type quality assurance expenses were reclassified from "selling expenses" to "cost of sales," with retrospective adjustments made to comparative period data[315](index=315&type=chunk) [Notes to Consolidated Financial Statement Items](index=91&type=section&id=Notes%20to%20Consolidated%20Financial%20Statement%20Items) This section provides detailed notes on consolidated financial statement items, including assets, liabilities, and equity, covering composition, changes, and impairment tests, essential for data comprehension - The top five accounts receivable balances at period-end accounted for **39.32%** of the total, with the second largest customer having full provision for bad debts[351](index=351&type=chunk) - Goodwill had a book value of **RMB 103 million**, primarily from the acquisition of Nanjing Kaitong, with an impairment provision of **RMB 7.597 million** already made[481](index=481&type=chunk)[483](index=483&type=chunk) - Assets with restricted ownership or use rights had a period-end book value of **RMB 25.385 million**, primarily consisting of financing transaction deposits[501](index=501&type=chunk)

海信家电集团股份有限公司 2025 年半年度报告 2025 年 7 月 海信家电集团股份有限公司 2025 年半年度报告全文 第一节 重要提示、目录和释义 公司董事会、监事会及董事、监事、高级管理人员保证半年度报告内容的 真实、准确、完整，不存在虚假记载、误导性陈述或者重大遗漏，并承担个别 和连带的法律责任。 公司负责人高玉玲、主管会计工作负责人孙长春及会计机构负责人(会计 主管人员)周珊声明：保证本半年度报告中财务报告的真实、准确、完整。 所有董事均已出席了审议本次半年报的董事会会议。 本半年度报告涉及未来计划等前瞻性陈述，不构成公司对投资者的实质承 诺，请投资者注意投资风险。 公司计划不派发现金红利，不送红股，不以公积金转增股本。 1 | 第一节 | 重要提示、目录和释义 | 1 | | --- | --- | --- | | 第二节 | 公司简介和主要财务指标 | 5 | | 第三节 | 管理层讨论与分析 | 8 | | 第四节 | 公司治理、环境和社会 | 33 | | 第五节 | 重要事项 | 37 | | 第六节 | 股份变动及股东情况 | 48 | | 第七节 | 债券相关情况 | 54 | | ...

Section I Definitions [Definitions of Common Terms](index=4&type=section&id=Definitions%20of%20Common%20Terms) This section provides definitions for key terms and abbreviations, including the company, affiliates, and regulatory bodies, essential for report comprehension - The report clarifies the designations of core companies and related parties such as **"Jiaoda Onlly," "Shanghai Yunjian," and "Dazhong Transportation"**[12](index=12&type=chunk) Section II Company Profile and Key Financial Indicators [Company Information](index=4&type=section&id=Company%20Information) This section provides the company's fundamental business registration details, including names, legal representative, and contact information - The company's full name is **Shanghai Jiaoda Onlly Co., Ltd.**, stock code **600530**, and legal representative is **Ji Min**[14](index=14&type=chunk)[19](index=19&type=chunk) [Key Accounting Data and Financial Indicators](index=5&type=section&id=Key%20Accounting%20Data%20and%20Financial%20Indicators) In H1 2025, the company experienced a performance decline with revenue down 5.77% and net profit attributable to shareholders decreasing by 30.54%, while operating cash flow turned negative, indicating significant cash flow pressure Key Accounting Data for H1 2025 | Item | Current Period (Jan-Jun) | Prior Period | Change (%) | | :--- | :--- | :--- | :--- | | Operating Revenue | 150,774,339.60 RMB | 160,012,804.82 RMB | -5.77% | | Net Profit Attributable to Shareholders of Listed Company | 2,248,634.38 RMB | 3,237,508.43 RMB | -30.54% | | Net Profit Attributable to Shareholders of Listed Company (Excluding Non-recurring Gains/Losses) | -2,128,457.43 RMB | -1,137,481.09 RMB | N/A | | Net Cash Flow from Operating Activities | -9,486,541.87 RMB | 21,701,949.08 RMB | -143.71% | | Total Assets | 736,926,378.63 RMB | 758,879,487.15 RMB | -2.89% (vs. end of previous year) | | Net Assets Attributable to Shareholders of Listed Company | 318,812,621.60 RMB | 325,711,012.85 RMB | -2.12% (vs. end of previous year) | Key Financial Indicators for H1 2025 | Item | Current Period (Jan-Jun) | Prior Period | Change (%) | | :--- | :--- | :--- | :--- | | Basic Earnings Per Share (RMB/share) | 0.0029 | 0.0042 | -30.95% | | Weighted Average Return on Net Assets (%) | 0.70% | 1.09% | Decreased by 0.39 percentage points | - During the reporting period, non-recurring gains and losses totaled **RMB 4.3771 million**, primarily from the reversal of loan impairment losses of **RMB 2.25 million** from Onlly Microcredit repayment, government subsidies, and non-operating income/expenses[23](index=23&type=chunk) Section III Management Discussion and Analysis [Main Business and Industry Overview](index=7&type=section&id=Explanation%20of%20the%20Company%27s%20Industry%20and%20Main%20Business%20During%20the%20Reporting%20Period) The company's main business comprises two segments: health products and medical care services, operating within the promising big health industry with strong growth prospects in probiotics and plant extracts - The company's main businesses include the **R&D, production, and sales of health products (including raw materials)**, and the **operation and management of elderly medical care institutions**[25](index=25&type=chunk) - The health product segment focuses on **probiotics and plant extracts**, with business models covering **B2C end-product sales and B2B raw material supply**[26](index=26&type=chunk)[27](index=27&type=chunk)[28](index=28&type=chunk) - The medical care segment primarily operates **self-managed elderly care institutions**, providing **medical, rehabilitation, and nursing services** for the elderly, and offers **external management consulting services**[31](index=31&type=chunk) - The industry outlook is broad, with China's big health industry expected to reach **RMB 16 trillion by 2030**, and the **probiotics and plant extract markets** maintaining rapid growth[29](index=29&type=chunk)[30](index=30&type=chunk) [Discussion and Analysis of Operations](index=8&type=section&id=Discussion%20and%20Analysis%20of%20Operations) During the reporting period, the health product segment expanded product lines, but raw material business declined due to competition and tariffs, while the medical care segment faced significant challenges from unilateral termination of management agreements and ongoing litigation - For health product end-products, the company expanded its **pet product line** and launched new **cognitive improvement and sports nutrition health products** on platforms like JD.com and Tmall[32](index=32&type=chunk)[33](index=33&type=chunk) - Raw material business performance slightly declined year-on-year due to **fierce domestic probiotics industry competition and North American tariff policy adjustments**, prompting the company to optimize personnel and production processes for cost reduction and efficiency improvement[34](index=34&type=chunk) - Several non-profit organizations under the medical care segment unilaterally terminated management consulting agreements and refused to pay management fees, preventing the company from obtaining related operating income; the company has filed a lawsuit, lost the first instance, appealed, and the second instance is ongoing, which has a **significant impact on the company's operations**[37](index=37&type=chunk)[59](index=59&type=chunk) [Analysis of Core Competencies](index=9&type=section&id=Analysis%20of%20Core%20Competencies%20During%20the%20Reporting%20Period) The company's core competencies lie in its health product segment's strong R&D, brand recognition, and diverse product lines, and its medical care segment's industry focus, professional service quality, and cost control capabilities - The core competencies of the health product segment include **strong R&D platforms and technologies for probiotics and plant extracts**, with **42 invention patents**; **brand advantages** from honors like "China Well-known Trademark"; a **diversified product line** covering health products, daily necessities, and pet products; and a **quality control system** with multiple international certifications[38](index=38&type=chunk)[39](index=39&type=chunk)[40](index=40&type=chunk)[42](index=42&type=chunk) - The core competencies of the medical care segment include **first-mover scale advantages** from long-term cultivation; a **reputation for high-quality services** from professional operating teams and standardized service systems; and **cost control advantages** established through data analysis systems[43](index=43&type=chunk)[44](index=44&type=chunk)[45](index=45&type=chunk) [Financial Analysis of Main Operations](index=10&type=section&id=Main%20Operating%20Conditions%20During%20the%20Reporting%20Period) This section analyzes the company's financial performance, noting a slight decrease in revenue and costs, a significant increase in R&D expenses, a negative shift in operating cash flow due to increased loan disbursements, and a substantial rise in loans and short-term borrowings Analysis of Major Financial Statement Item Changes | Item | Current Period Amount | Prior Period Amount | Change Ratio (%) | | :--- | :--- | :--- | :--- | | Operating Revenue | 150,774,339.60 RMB | 160,012,804.82 RMB | -5.77 | | R&D Expenses | 3,224,872.44 RMB | 2,280,318.27 RMB | 41.42 | | Net Cash Flow from Operating Activities | -9,486,541.87 RMB | 21,701,949.08 RMB | -143.71 | | Loans and Advances | 43,500,000.00 RMB | 4,250,000.00 RMB | 923.53 (vs. end of previous year) | | Short-term Borrowings | 36,026,307.22 RMB | 20,024,444.44 RMB | 79.91 (vs. end of previous year) | - The significant decrease in **net cash flow from operating activities** was primarily due to an **increase in net loans disbursed** by the investment and financing segment during the current period[46](index=46&type=chunk) - The company established a wholly-owned subsidiary, **"Onlly International Trading Co., Ltd."** in Hong Kong, with an actual investment of **HKD 10 million**, aiming to develop cross-border e-commerce and international trade businesses[50](index=50&type=chunk)[51](index=51&type=chunk) Operating Performance of Major Holding and Participating Companies (Unit: RMB Million) | Company Name | Main Business | Operating Revenue | Net Profit | | :--- | :--- | :--- | :--- | | Shanghai Nuode Bio-Industry Co., Ltd. | Natural Plant Products | 45.2254 | 7.0653 | | Shanghai Bairen Yinggang Nursing Home Co., Ltd. | Rehabilitation Medicine, etc. | 29.2502 | 3.2387 | | Ningbo Jiangbei Kangyang Hospital Co., Ltd. | Rehabilitation Medicine, etc. | 23.5923 | 3.2726 | | Shanghai Xuhui Onlly Microcredit Co., Ltd. | Loans | 0.00 | 3.1433 | [Potential Risks](index=14&type=section&id=Potential%20Risks) The company faces specific risks in its health product segment, including intense competition and regulatory changes, while the medical care segment is exposed to policy shifts, rising labor costs, and significant litigation risks from contract disputes - The health product segment faces multiple risks including **industry competition, regulatory policies, talent gaps, cost pressures, and international political situations (tariffs)**[57](index=57&type=chunk) - The medical care segment faces risks from **changes in medical insurance and long-term care insurance policies** and **rising labor costs**; the most significant risk is the **unilateral termination of management agreements by affiliated non-profit organizations** and their refusal to pay, with ongoing litigation potentially preventing the company from continuing to obtain operating income[59](index=59&type=chunk) Section IV Corporate Governance, Environment, and Society [Changes in Directors, Supervisors, and Senior Management](index=15&type=section&id=Changes%20in%20Directors%2C%20Supervisors%2C%20and%20Senior%20Management) During the reporting period, Mr. Du Gang, a non-independent director, resigned from his positions due to personal reasons on June 26, 2025 - On **June 26, 2025**, non-independent director **Mr. Du Gang resigned** due to personal reasons[61](index=61&type=chunk) [Profit Distribution Plan](index=15&type=section&id=Profit%20Distribution%20or%20Capital%20Reserve%20Conversion%20Plan) The company has no profit distribution or capital reserve conversion plan for the first half of 2025 - No profit distribution or capital reserve conversion is planned for the half-year period[62](index=62&type=chunk) Section V Significant Matters [Fulfillment of Commitments](index=17&type=section&id=Fulfillment%20of%20Commitments) During the reporting period, the acquirer Shanghai Shijie and its concerted parties strictly fulfilled their commitments regarding avoiding horizontal competition and regulating related-party transactions - Commitments made in the acquisition report regarding **avoiding horizontal competition and regulating related-party transactions** were strictly fulfilled[66](index=66&type=chunk)[67](index=67&type=chunk) [Major Litigation and Arbitration Matters](index=19&type=section&id=Major%20Litigation%20and%20Arbitration%20Matters) The company is involved in several major litigations, including a withdrawn civil suit against former executives now a criminal report, and a third-party involvement in a joint venture's debt transfer dispute, with the most critical being ongoing appeals related to management contract disputes with non-profit nursing homes - The company's lawsuit against former directors and senior executives Yang Guoping and others for **damaging company interests** has been withdrawn and converted into a **criminal report to the public security organs**, but it has not been filed, and the company has applied for reconsideration[68](index=68&type=chunk) - The company participated as a third party in the **debt transfer contract dispute case** involving its associate company, **Shanghai Xuhui Onlly Microcredit Co., Ltd.**[68](index=68&type=chunk) [Regulatory Penalties and Rectification Status](index=19&type=section&id=Suspected%20Violations%2C%20Penalties%2C%20and%20Rectification%20Status%20of%20Listed%20Company%2C%20its%20Directors%2C%20Supervisors%2C%20Senior%20Management%2C%20Controlling%20Shareholder%2C%20and%20Actual%20Controller) In January 2025, the company and relevant former senior executives received a regulatory warning from the Shanghai Stock Exchange, prompting the company to implement rectification measures including strengthening internal controls and establishing a new auditor selection system - On **January 2, 2025**, the company and several former senior executives received a **regulatory warning from the Shanghai Stock Exchange**[69](index=69&type=chunk) - The company has undertaken rectification measures, including **strengthening internal controls, streamlining approval processes**, and approving the **"Accountant Firm Selection System"**[70](index=70&type=chunk) [Other Significant Matters](index=23&type=section&id=Explanation%20of%20Other%20Significant%20Matters) On July 11, 2025, the company received a "Notice of Case Filing" from the China Securities Regulatory Commission, indicating an ongoing investigation which the company will actively cooperate with - On **July 11, 2025**, the company received a **"Notice of Case Filing"** (No. CSRC Case Filing [2025] 024) from the China Securities Regulatory Commission, indicating that the company is **under investigation**[77](index=77&type=chunk) Section VI Share Changes and Shareholder Information [Share Capital Change Status](index=23&type=section&id=Share%20Capital%20Change%20Status) During the reporting period, there were no changes in the company's total share capital or share structure - During the reporting period, there were **no changes** in the company's total share capital or share structure[79](index=79&type=chunk) [Shareholder Information](index=23&type=section&id=Shareholder%20Information) As of the end of the reporting period, the company had 26,322 shareholders, with Shanghai Yunjian and its concerted parties holding 30.06% as the largest shareholder, and Dazhong Transportation and its concerted parties holding 19.88% - As of the end of the reporting period, the company had **26,322 common shareholders**[80](index=80&type=chunk) Top Ten Shareholders' Shareholding | Shareholder Name | Shares Held at Period End | Percentage (%) | | :--- | :--- | :--- | | Dazhong Transportation (Group) Co., Ltd. | 112,184,187 | 14.48 | | Shanghai Yunjian Industrial Development Co., Ltd. | 94,048,695 | 12.14 | | Shanghai Shijie Decoration Design Engineering Co., Ltd. | 53,248,817 | 6.87 | | Shanghai Xinluda Commercial (Group) Co., Ltd. | 47,993,727 | 6.19 | | Lishui Xincheng Xinchuang Technology Development Partnership (Limited Partnership) | 45,133,650 | 5.82 | - There are two major concerted party groups among shareholders: **Shanghai Yunjian and its concerted parties** collectively hold **30.06%**; **Dazhong Transportation and its concerted parties** collectively hold **19.88%**[83](index=83&type=chunk) - In **February 2025**, **Shanghai Shijie completed a partial tender offer** for the company, after which its total shareholding with concerted parties reached **30.0620%**[84](index=84&type=chunk)[85](index=85&type=chunk) Section VII Bond-Related Information [Bond Status](index=26&type=section&id=Corporate%20Bonds%20and%20Non-Financial%20Enterprise%20Debt%20Financing%20Instruments) During the reporting period, the company had no outstanding corporate bonds, enterprise bonds, non-financial enterprise debt financing instruments, or convertible corporate bonds - The company has **no outstanding corporate bonds, enterprise bonds, non-financial enterprise debt financing instruments, or convertible corporate bonds**[89](index=89&type=chunk) Section VIII Financial Report [Financial Statements](index=27&type=section&id=Financial%20Statements) This chapter provides the company's unaudited H1 2025 consolidated and parent company financial statements, including balance sheets, income statements, cash flow statements, and statements of changes in owners' equity, showing total assets of RMB 737 million, operating revenue of RMB 151 million, net profit attributable to parent of RMB 2.25 million, and negative operating cash flow of RMB 9.49 million Consolidated Balance Sheet Summary (June 30, 2025) | Item | Amount (RMB) | | :--- | :--- | | Total Assets | 736,926,378.63 | | Total Liabilities | 366,299,579.70 | | Total Owners' Equity Attributable to Parent Company | 318,812,621.60 | Consolidated Income Statement Summary (Jan-Jun 2025) | Item | Amount (RMB) | | :--- | :--- | | Total Operating Revenue | 150,774,339.60 | | Total Profit | 6,995,875.44 | | Net Profit Attributable to Parent Company Shareholders | 2,248,634.38 | Consolidated Cash Flow Statement Summary (Jan-Jun 2025) | Item | Amount (RMB) | | :--- | :--- | | Net Cash Flow from Operating Activities | -9,486,541.87 | | Net Cash Flow from Investing Activities | -158,887.97 | | Net Cash Flow from Financing Activities | -7,800,388.16 | | Net Increase in Cash and Cash Equivalents | -17,440,147.17 | [Significant Accounting Policies and Estimates](index=45&type=section&id=Significant%20Accounting%20Policies%20and%20Estimates) This chapter details the company's significant accounting policies and estimates, including consolidation methods, financial instrument classification, expected credit loss models, inventory valuation, long-term equity investments, revenue recognition, and lease accounting, all in accordance with Chinese accounting standards - Financial statements are prepared on a **going concern basis**, adhering to **Chinese Enterprise Accounting Standards**[124](index=124&type=chunk)[125](index=125&type=chunk)[127](index=127&type=chunk) - The company uses the **expected credit loss model** to accrue impairment provisions for financial assets, and for receivables without significant financing components, it applies a **simplified approach** to measure expected credit losses over their entire lifetime[167](index=167&type=chunk)[176](index=176&type=chunk) - Revenue recognition follows the **new revenue standards**, recognized when the customer obtains control of the related goods or services; health product sales are recognized upon **delivery or settlement** based on different models (buyout, consignment, online); medical care services are recognized **over the period of service provision**[234](index=234&type=chunk)[237](index=237&type=chunk) [Notes to Consolidated Financial Statement Items](index=72&type=section&id=Notes%20to%20Consolidated%20Financial%20Statement%20Items) This chapter provides detailed explanations and data breakdowns for major consolidated financial statement items, highlighting that 40.24% of accounts receivable were fully impaired, loans and advances significantly increased, and a full impairment provision was made for RMB 361 million in operating income rights due to contract disputes - At period-end, the book balance of accounts receivable was **RMB 65.45 million**, of which **RMB 26.34 million (40.24%)** was fully impaired individually due to expected uncollectibility[265](index=265&type=chunk)[266](index=266&type=chunk) - The period-end balance of **loans and advances was RMB 43.50 million**, a significant increase from **RMB 4.25 million** at the beginning of the period, primarily due to new loans disbursed in the current period[299](index=299&type=chunk) - Due to contract disputes with several non-profit organizations, the company has fully accrued impairment provisions for **operating income rights** (listed under other non-current assets) with a book original value of **RMB 361 million**[348](index=348&type=chunk)[349](index=349&type=chunk) - At period-end, the book original value of goodwill was **RMB 193 million**, with impairment provisions of **RMB 83 million**, and a net value of **RMB 54.87 million**, with **no new impairment** recognized during the reporting period[333](index=333&type=chunk)[335](index=335&type=chunk) [Related Parties and Related Party Transactions](index=134&type=section&id=Related%20Parties%20and%20Related%20Party%20Transactions) This chapter discloses the company's related party relationships and transactions, identifying Shanghai Yunjian and its concerted parties as the largest shareholder, noting minor related-party sales, and detailing impaired receivables from non-profit organizations and outstanding loans to an associate - The company's largest shareholder is **Shanghai Yunjian Industrial Development Co., Ltd.** and its concerted parties, collectively holding **30.06%**, with **Mr. Ji Lin** as the ultimate controlling person[444](index=444&type=chunk)[445](index=445&type=chunk) - During the reporting period, the amount of **goods purchase and sales transactions with related parties was small**[447](index=447&type=chunk)[448](index=448&type=chunk) - At period-end, accounts receivable from several affiliated non-profit organizations were **fully impaired**; loans and advances to associate **Shanghai Xuhui Onlly Microcredit Co., Ltd.** had a book balance of **RMB 14 million**, with an impairment provision of **RMB 10.5 million**[456](index=456&type=chunk)[457](index=457&type=chunk) [Commitments and Contingencies](index=140&type=section&id=Commitments%20and%20Contingencies) This chapter discloses the company's significant commitments, primarily a RMB 10 million short-term guaranteed loan, and major contingencies, specifically ongoing appeals in lawsuits with seven non-profit organizations regarding management service agreements, which pose significant uncertainty to future earnings - The company has a **RMB 10 million short-term guaranteed loan**, secured by its wholly-owned subsidiary **Shanghai Nuode Bio-Industry Co., Ltd.**[461](index=461&type=chunk) - The company has a **significant contingency** involving ongoing lawsuits with **seven non-profit organizations** regarding the validity of "Equity Transfer Agreements" and "Management Consulting Service Agreements"; the first instance ruling did not support the company's claims, and the company has appealed, with the second instance still ongoing, which may prevent the company from obtaining related operating income[462](index=462&type=chunk)[463](index=463&type=chunk)[464](index=464&type=chunk)[465](index=465&type=chunk)[466](index=466&type=chunk)[467](index=467&type=chunk)[469](index=469&type=chunk)

海南双成药业股份有限公司 2025 年半年度报告全文 海南双成药业股份有限公司 2025 年半年度报告 2025 年 07 月 1 海南双成药业股份有限公司 2025 年半年度报告全文 第一节 重要提示、目录和释义 公司董事会及董事、高级管理人员保证半年度报告内容的真实、准确、 完整，不存在虚假记载、误导性陈述或者重大遗漏，并承担个别和连带的法 律责任。 公司负责人王成栋、主管会计工作负责人王旭光及会计机构负责人(会计 主管人员)周云声明：保证本半年度报告中财务报告的真实、准确、完整。 所有董事均已出席了审议本次半年报的董事会会议。 本半年度报告中涉及未来计划等前瞻性描述，不构成公司对投资者的实 质承诺，投资者及相关人士均应当对此保持足够的风险认识，并且应当理解 计划、预测与承诺之间的差异。 本公司存在行业政策变化风险、药品降价风险、原材料和辅料价格上涨 风险、固定资产折旧增加导致利润下降的风险、环保风险、产品价格风险、 药品质量风险、人才流失风险、财务风险、公共卫生事件影响、资产减值风 险、国际贸易环境风险、股票可能被终止上市的风险提示等风险，具体内容 在本报告"第三节 管理层讨论与分析"之"十、公司面临的 ...